Outlook Therapeutics’ second attempt to obtain US approval for its wet age-related macular degeneration (wet AMD) therapy, Lytenava (bevacizumab-vikg) has suffered a setback as the therapy ...

According to reports, Belanger is a believer in Ocular mainly on the potential of its investigational Axpaxli, a drug that ...

Age-related macular (AMD) degeneration is a leading cause of vision impairment and blindness in the elderly population.

D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and ...

Needham initiated coverage on Ocular Therapeutix Inc (NASDAQ:OCUL), noting the company’s lead asset, Axpaxli, an investigational axitinib-based intravitreal implant for wet age-related macular ...

New research shows that eating this tasty snack daily can help protect against the leading cause of vision loss in older ...

Ocular Therapeutix's Axpaxli targets wet AMD with long-acting treatment. Click here to find out why OCUL stock is a Strong ...

The United States Court of Appeals for the First Circuit recently joined the Sixth Circuit (2023) and Eighth Circuit (2022) ...

Wet AMD remains the leading cause of vision loss ... The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialization and a significant ...

The wet AMD market exceeds $12 billion ... minutes from its recent End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) relating to CLS-AX (axitinib injectable suspension ...

CLS-AX Phase 3 Program Designed to Maximize Commercial Potential in Wet AMD -- Flexible Dosing and Extended Duration would be Important ...